NCT01573377.

Methods	Randomised controlled trial
Participants	Inclusion criteria: at least two of the following features: (i) oligo‐amenorrhoea or chronic anovulation; (ii) clinical and/or biochemical hyperandrogenism; (iii) ultrasound appearance of polycystic ovaries Exclusion criteria: other known causes of hyperandrogenaemia and ovulatory dysfunction, including 21‐hydroxylase deficiency, congenital adrenal hyperplasia, Cushing's syndrome, androgen‐secreting tumours, thyroid disease, and hyperprolactinaemia. use of hormone medications (including oral contraceptives) within the past month and the use of medicines that affect insulin sensitivity (e.g. metformin or thiazolidinediones) within the past three months
Interventions	Treatment: MET 425 mg twice daily/ one week then 850 mg twice daily Control: OCP (Ethinyl Estradiol 35 mcg/cyproterone acetate 2 mg)
Outcomes	(a) Clinical parameters Menstrual cycle (b) Metabolic parameters Fasting insulin (IU/mL)
Notes	Completed, email sent to the authors to have the publication references because not found in databases.